EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

COVID-19 SARS Treatment with Ruxolitinib; Ongoing Trial and Method

Roberto Ovilla-Martínez, Xóchitl Cota-Rangel, José Antonio de la Peña-Celaya, Pamela Elena Baez-Islas

Latin american journal of clinical sciences and medical technology · 2020

DOI: 10.34141/ljcs1293860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Latin american journal of clinical sciences and medical technology, 2020. Verfasst von Roberto Ovilla-Martínez und 3 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Due to a high rate of contagion, COVID-19 has become a pandemic with an increasing rate of hospitalization and mortality. The main complication is the hyperimmune response caused by the pro-inflammatory cytokines like IL-1, IL-6, IFN-g, and TNF-a. Therefore, one of the principal therapeutic targets in COVID-19 is to stop the hyperimmune response. The JAK 1/2 inhibitor, ruxolitinib, suppress cytotoxic T-cells and pro-inflammatory cytokines like IL-6. Material and Methods. This clinical trial uses ruxolitinib in an open-label study to demonstrate the efficacy and safety of the drug on COVID-19 pneumonia with an initial population of 77 patients. The primary objective is to measure the clinical response in patients with pulmonary lesions caused by COVID-19 defined the changes in oxygenation measured by SpO2 or Pa/FiO2. The secondary objectives will be to observe the pro-inflammatory state by measuring C- reactive protein, ferritin, lactate dehydrogenase, D-dimer, hospitalization rate, length, and mortality. The safety outcomes to analyze are cytopenias and liver test abnormalities.

Conclusions

The JAK inhibitors are drugs with anti-inflammatory characteristics for diverse pathologies. The use of ruxolitinib seems promising in controlling the cytokine storm observed in patients with severe COVID-19. This trial is registered on clinicaltrials.gov (NCT04334044).

Zitieren

APA

Ovilla-Martínez, R., Cota-Rangel, X., Peña-Celaya, J. A. D. L., & Baez-Islas, P. E. (2020). COVID-19 SARS Treatment with Ruxolitinib; Ongoing Trial and Method. Latin american journal of clinical sciences and medical technology. https://doi.org/10.34141/ljcs1293860

Vancouver

Ovilla-Martínez R, Cota-Rangel X, Peña-Celaya JADL, Baez-Islas PE. COVID-19 SARS Treatment with Ruxolitinib; Ongoing Trial and Method. Latin american journal of clinical sciences and medical technology. 2020. doi:10.34141/ljcs1293860

BibTeX
@article{OvillaMartnez2020,
  author = {Ovilla-Martínez, Roberto and Cota-Rangel, Xóchitl and Peña-Celaya, José Antonio de la and Baez-Islas, Pamela Elena},
  title = {COVID-19 SARS Treatment with Ruxolitinib; Ongoing Trial and Method},
  journal = {Latin american journal of clinical sciences and medical technology},
  year = {2020},
  doi = {10.34141/ljcs1293860}
}
Kostenlos starten →